Search

Owing to significantly prolonged survival, targeted therapy has become standardized recommendation for advanced non-small cell lung cancer patients with mutated driver genes. However, the genetic status of lung cancer patients is dynamic. By dynamically monitoring the evolution of genes status, differential genes and concomitant genes related to progressive disease could be confirmed early, so as to achieve a more accurate and comprehensive insight of the whole process management of targeted therapy for lung cancer patients. Under the guidance of accurate genetic testing results, it is helpful to provide patients with more effective, long-term, and stable individualized targeted therapy. [ABSTRACT FROM AUTHOR]